SCHEMBL118658

SCHEMBL118658

CCOC(=O)c1cn2cc(O)ccc2n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.66
POLB P06746 1/20 0.66
GAA P10253 1/20 0.56
RAB9A P51151 5/20 0.53
ALDH1A1 P00352 1/20 0.51
HPGD P15428 1/20 0.51
NPC1 O15118 3/20 0.51
RXFP1 Q9HBX9 1/20 0.51
KMT2A Q03164 2/20 0.50
CYP1A2 P05177 1/20 0.50
MAPT P10636 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
ESR1 P03372 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
ESR2 Q92731 1/20 0.47
CA14 Q9ULX7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL871014 0.88 KDM4E (0.69) KDM4EPOLBGAARAB9AALDH1A1
SCHEMBL4098270 0.84 KDM4E (0.64) KDM4EPOLBGAARAB9AALDH1A1
SCHEMBL3545619 0.84 KDM4E (0.64) KDM4EPOLBGAARAB9AALDH1A1
SCHEMBL70705 0.84 KDM4E (0.64) KDM4EPOLBGAARAB9AALDH1A1
SCHEMBL741904 0.84 KDM4E (0.64) KDM4EPOLBGAARAB9AALDH1A1
SCHEMBL1500236 0.84 KDM4E (0.64) KDM4EPOLBGAARAB9AALDH1A1
Hydrochloric Acid SCHEMBL21223028 0.82 KDM4E (0.63) KDM4EPOLBGAARAB9AALDH1A1
SCHEMBL21033471 0.82 KDM4E (0.63) KDM4EPOLBGAARAB9AALDH1A1
SCHEMBL2086625 0.82 KDM4E (0.63) KDM4EPOLBGAARAB9AALDH1A1
SCHEMBL19389669 0.82 KDM4E (0.63) KDM4EPOLBGAARAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612412-B2 Antiviral heterocyclic compounds ENANTA PHARMACEUTICALS, INC. (US) 2026-04-28 US disclosed
US-12421225-B2 Heteroaromatic amide derivative and medicament containing the same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2025-09-23 US disclosed
EP-4612151-A1 PREPARATION OF IMIDAZOPYRIDINE AND IMIDAZOPYRIDAZINE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS Merck Sharp & Dohme LLC (US) 2025-09-10 EP disclosed
CN-112689636-B Novel heteroatom aromatic amide derivative and pharmaceutical agent containing same 科研制药株式会社 2024-08-20 CN disclosed
CN-118434744-A Nitrogen-containing macrocyclic compound, and preparation method and medical application thereof 中国医药研究开发中心有限公司 2024-08-02 CN disclosed
EP-3851436-B1 NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMA CO LTD (JP) 2024-06-12 EP disclosed
WO-2024097573-A1 PREPARATION OF IMIDAZOPYRIDINE AND IMIDAZOPYRIDAZINE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS MERCK SHARP & DOHME LLC (US) 2024-05-10 WO disclosed
US-11945830-B2 Antiviral heterocyclic compounds ENANTA PHARMACEUTICALS, INC. (US) 2024-04-02 US disclosed
WO-2024046512-A2 NITROGEN-CONTAINING MACROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 中国医药研究开发中心有限公司 2024-03-07 WO disclosed
EP-4298103-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS Enanta Pharmaceuticals, Inc. (US) 2024-01-03 EP disclosed
WO-2023200441-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ENANTA PHARMACEUTICALS, INC. (US) 2023-10-19 WO disclosed
US-20230115580-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ENANTA PHARMACEUTICALS, INC. 2023-04-13 US disclosed
US-20230108803-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ENANTA PHARMACEUTICALS, INC. 2023-04-06 US disclosed
US-20230086366-A1 Novel heteroaromatic amide derivative and medicament containing the same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2023-03-23 US disclosed
WO-2022182861-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ENANTA PHARMACEUTICALS, INC. (US) 2022-09-01 WO disclosed
EP-3851436-A1 NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME Kaken Pharmaceutical Co., Ltd. (JP) 2021-07-21 EP disclosed
US-20120101093-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-04-26 US disclosed
EP-2424866-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS -SECRETASE INHIBITORS High Point Pharmaceuticals, LLC (US) 2012-03-07 EP disclosed
WO-2010126745-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS β-SECRETASE INHIBITORS HIGH POINT PHARMACEUTICALS, LLC (US) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230086366-A1 Novel heteroaromatic amide derivative and medicament containing the same SCN7A, HCN4, SCN4A KDM4E 2290/4885POLB 3414/4885GAA 3381/4885
US-12421225-B2 Heteroaromatic amide derivative and medicament containing the same SCN7A, HCN4, SCN4A KDM4E 2231/4885POLB 3234/4885GAA 3549/4885
US-20120101093-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS BACE1, BACE2, APP KDM4E 2967/4885POLB 1028/4885GAA 30/4885
US-12612412-B2 Antiviral heterocyclic compounds ZC3HAV1, NHERF1, HM13 KDM4E 342/4885POLB 1836/4885GAA 4300/4885
US-20230115580-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ACE, HPRT1, ACE2 KDM4E 1648/4885POLB 2743/4885GAA 1445/4885
US-20230108803-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ACE, HPRT1, ACE2 KDM4E 1648/4885POLB 2743/4885GAA 1445/4885
US-11945830-B2 Antiviral heterocyclic compounds ACE, HPRT1, ACE2 KDM4E 1648/4885POLB 2743/4885GAA 1445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.